|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM315325143 |
| 003 |
DE-627 |
| 005 |
20231225154653.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108595
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1051.xml
|
| 035 |
|
|
|a (DE-627)NLM315325143
|
| 035 |
|
|
|a (NLM)32961330
|
| 035 |
|
|
|a (PII)S1521-6616(20)30755-5
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kakoullis, Loukas
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Infection-induced myeloperoxidase specific antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis
|b A systematic review
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.05.2021
|
| 500 |
|
|
|a Date Revised 14.05.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a BACKGROUND: We conducted a systematic review to identify cases of infection-induced anti-myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
|
| 520 |
|
|
|a METHODS: PubMed/Medline databases were searched from inception to July of 2020, according to PRISMA guidelines
|
| 520 |
|
|
|a RESULTS: Among the 618 abstracts identified, 18 articles describing 23 patients (60.9% female, mean age 50.5 years) were included. Median time between infection and vasculitis development was 3 months. Five (21.7%) patients expired during follow-up. Vasculitis regressed after the resolution of infection in 12/23 (52.2%). ANCA titers decreased significantly on follow-up in 14/16 patients and in all survivors in which they were measured. Pathogens reported included Mycobacterium spp., Coccidioides spp., Rickettsia rickettsii, Staphylococcus spp., EBV, CMV and Dengue virus
|
| 520 |
|
|
|a CONCLUSIONS: MPO-AAV can occur after infection and may regress after its resolution. Infection should be considered in cases of MPO-AAV, as immunosuppressive treatment can have catastrophic results if the infection is not adequately treated
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Systematic Review
|
| 650 |
|
4 |
|a Infection
|
| 650 |
|
4 |
|a Microscopic polyangiitis
|
| 650 |
|
4 |
|a Pathogenesis
|
| 650 |
|
4 |
|a Vasculitis
|
| 650 |
|
4 |
|a Virus
|
| 650 |
|
7 |
|a Immunosuppressive Agents
|2 NLM
|
| 650 |
|
7 |
|a Peroxidase
|2 NLM
|
| 650 |
|
7 |
|a EC 1.11.1.7
|2 NLM
|
| 700 |
1 |
|
|a Parperis, Konstantinos
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Papachristodoulou, Eleni
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Panos, George
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 220(2020) vom: 01. Nov., Seite 108595
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:220
|g year:2020
|g day:01
|g month:11
|g pages:108595
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108595
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 220
|j 2020
|b 01
|c 11
|h 108595
|